Last year, the pharmaceutical industry spent about $2 billion on assorted R&D activities in India, but that figure is expected to reach a whopping $25 billion by 2025. The reasons are varied, but can be traced to expanding activities by Indian companies, addtional government investment and a growing pool of qualified researchers, according to a new report by the Boston Consulting Group.
